RXST — RxSight, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1111485 ·
Last close
$6.01
Market Cap
$248.79M
52W High
$7.49
52W Low
$4.48
ADV30
1,358,888
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 30,893,000 | 23,498,000 | -17,829,000 | -15,884,000 | 303,993,000 | 17,573,000 | 36,698,000 |
| Dec 2025 | 32,608,000 | 25,263,000 | -11,337,000 | -9,152,000 | 311,814,000 | 19,949,000 | 36,131,000 |
| Sep 2025 | 30,340,000 | 24,227,000 | -12,178,000 | -9,816,000 | 308,533,000 | 29,633,000 | 32,563,000 |
| Jun 2025 | 33,637,000 | 25,190,000 | -14,003,000 | -11,786,000 | 309,009,000 | 40,355,000 | 30,997,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,511,000
Investing CF
$16,889,000
Financing CF
$1,863,000
CapEx
$-3,830,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.95
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-661,039,000
Inventory
$31,559,000
Receivables
$23,383,000
ST Investments
$208,179,000
EBIT TTM
$-38,859,000
Pretax Income TTM
$-38,879,000
Interest Exp TTM
$20,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$127,477,000
EBITDA
$-52,022,000
Free Cash Flow
$-969,250
Enterprise Value
$44,637,384
Total Cash
$217,880,000
Total Debt
$10,826,000
Shares Out
41,396,609
Trailing EPS
$-1.13
Book Value
$6.46
ROE
-17.1%
ROA
-11.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 134,479,000 | -48,191,000 | -38,944,000 | 311,814,000 | 36,131,000 | — | -15,511,000 |
| Dec 2024 | 139,927,000 | -36,858,000 | -27,455,000 | 318,563,000 | 37,325,000 | — | -16,946,000 |
| Dec 2023 | 89,077,000 | -50,085,000 | -48,608,000 | 182,550,000 | 22,188,000 | — | -41,593,000 |
| Dec 2022 | 49,005,000 | -63,318,000 | -66,756,000 | 150,164,000 | 60,262,000 | — | -58,850,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.67
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $6.01 · call oi: 1,011 · put oi: 231
Expected Move to 2026-08-21:
±$1.05
(17.47%) —
implied range
$4.96 –
$7.06
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JRS | NUVEEN REAL ESTATE INCOME FUND | $249.34M | $8.63 | — |
| GLO | Clough Global Opportunities Fund | $249.75M | $5.84 | — |
| NUW | Nuveen AMT-Free Municipal Value Fund | $250.60M | $13.96 | — |
| FCT | FIRST TRUST SENIOR FLOATING RATE INCOME FUND II | $250.74M | $9.65 | — |
| NHS | Neuberger High Yield Strategies Fund Inc. | $251.13M | $6.00 | — |
News headlines (Yahoo Finance, 1h cache)
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
2026-07-29 14:00 · Yahoo
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
2026-07-26 20:00 · Yahoo
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut
2026-07-25 20:06 · Yahoo
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
2026-07-17 07:50 · Yahoo
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
2026-07-15 20:15 · Yahoo
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
2026-07-11 02:01 · Yahoo
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones?
2026-07-08 14:50 · Yahoo
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
2026-07-06 20:15 · Yahoo
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
2026-07-06 20:15 · Yahoo
National Vision and Smart Glasses: Early Investing Signals
2026-06-03 14:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.